Oruka Therapeutics, Inc. announced progress in its clinical programs with ORKA-001 and ORKA-002, targeting chronic skin diseases like psoriasis. The company completed dosing in a Phase 1 trial for ...
Approvable population of ulcerative colitis (UC) patients for upcoming Phase 3 trials agreed upon with the U.S. Food and Drug Administration (FDA) Analysis of Phase 2 data using approvable UC patient ...
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral ...
The pharmaceutical industry is at a critical turning point. Drug discovery has evolved rapidly, but clinical development remains slow, expensive, and inefficient. Clinical trials, especially ...
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of ...
Werewolf Therapeutics provided a business update highlighting key milestones for 2025 regarding its clinical development programs. The company is expecting to release data from the Phase 1/1b clinical ...
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...
Cambridge, MA., Feb. 6, 2026 — Insilico Medicine (“Insilico”) (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results